|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||145.8 kg/mol g·mol−1|
Enoblituzumab is a monoclonal antibody designed for the treatment of cancer. Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.
This drug was developed by MacroGenics, Inc.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|